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Abstract  
Aims: To determine the “real world” relapse rate in patients with first-episode 
psychosis who had discontinued antipsychotic medication and identify socio-
demographic and clinical factors associated with the risk of relapse. Methods: 
Quantitative data were obtained via case-note review on 63 patients with first-
episode psychosis who had discontinued antipsychotic medication from 
Birmingham Early Intervention Service between 2012 and 2015. The follow-up 
period was until either: an occurrence of a relapse; end of 12 month study 
period; end of patient’s case-note record. Relapse was defined as a return of 
symptoms requiring: home treatment, hospital admission or was based on 
clinical teams’ decision as having a relapse.  A pro-forma targeted pre-defined 
socio-demographic and clinical factors. Survival analysis was undertaken to 
estimate the 12 month relapse rate following discontinuation of antipsychotics 
and Cox regression performed to identify relapse predictors. Results: The 
Kaplan-Meier 12 month relapse estimate was 67% (95% confidence interval, 
54%, 80%). Significant factors (P <0.05) independently associated with an 
increased risk of relapse following discontinuation of antipsychotic medication 
were: male gender, not being in education, employment or training (NEET) and 
number of previous psychiatric hospital admissions. Conclusions: Relapse is 
common after discontinuation of antipsychotic medication following recovery 
from a first-episode psychosis. It is important patients who wish to discontinue 
their medication are informed of the high relapse rates and the associated risks. 
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Furthermore, male patients, patients with NEET status and those who have had 
previous hospital admissions may require closer monitoring. 
 
Keywords: antipsychotics, discontinuation, first-episode psychosis, relapse, 
risk factors. 
 
Introduction  
Preventing relapse is one of the most important clinical targets in the 
management of first-episode psychosis (FEP); approximately 80% of patients 
treated following FEP, relapse within the first five years. 1,2 Relapse 
compromises the outcome of psychotic disorders, with each new episode 
significantly increasing the development of treatment resistant symptoms.  
It has been well established that maintenance medication plays an important 
role in reducing the risk of relapse among FEP patients.3 However, the optimum 
duration of maintenance medication is yet to be determined and published 
guidelines are not united in their recommendations. A recent systematic review 
of 14 guidelines for maintenance treatment after a first-episode of schizophrenia 
found that six were not opposed to discontinuing antipsychotics after one to two 
years, while two discouraged discontinuation4. In the remaining six guidelines, 
medication discontinuation was not mentioned.4 
The question of how long to continue antipsychotic treatment after FEP is 
common among patients, and clinicians face difficulties convincing patients that 
indefinite treatment may be indicated. Premature discontinuation of medication 
is common among patients; a randomised controlled trial comparing atypical 
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antipsychotics in FEP patients reported 70% of patients discontinued before the 
end of the 12 month study period.5  
Given the high rates of discontinuation reported, clinical interest in the 
relationship between relapse risk and discontinuation of medication in patients 
with FEP has grown. Controlled trials of treatment discontinuation consistently 
report higher relapse rates compared to maintenance treatment. However, 
studies to date have yielded a range of relapse rates (between 41% and 80%) 
following 12 months discontinuation.3,6-8 A systematic review estimated a 
weighted mean one-year relapse rate of 77% in six controlled trials.9 However 
the generalisability of these studies may be limited as patients required capacity 
to consent for inclusion, and, as volunteers, reflected a research population. 
Therefore, discontinuation relapse rates from a “real world” setting (i.e. 
representing clinical practice) may differ considerably. 
In addition to the clinical importance of estimating relapse rates representative 
of all patients who discontinue antipsychotic medication, it is also essential to be 
able to predict relapse risk. To date, medication non-adherence has been the 
only factor to robustly predict relapse in FEP patients, and is associated with a 
four-fold increase in relapse risk.10 The other risk factors associated with 
relapse include persistent substance use disorder, carers’ critical comments 
and poor premorbid adjustment10. Demographic and clinical variables such as 
younger age at first onset psychosis11, duration of untreated psychosis12 and 
male gender13,14 have been reported by some naturalistic studies to predict 
relapse, although these have failed to be replicated in later studies.2,15-17 It has 
been proposed that there may be relapse predictors specific to patients who 
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discontinue medication.3 It is imperative to be able to accurately predict relapse 
in these patients in order to allow identification of those at higher risk.  
 
Thus, this study has two main objectives: first, to determine the “real world” 
relapse rate in patients with FEP who had discontinued antipsychotic 
medication, and second, to identify the socio-demographic and clinical factors 
associated with the risk of relapse.  
Method  
Study setting and population 
The study population was drawn from patients under the care of the 
Birmingham Early Intervention Service (EIS) between 2012 and 2015. The EIS 
is responsible for the treatment of young people aged 16 - 35 with FEP. With a 
total caseload of approximately 700 patients, the service comprises five teams 
spanning the Birmingham and Solihull Mental Health Trust (BSMHFT); an area 
of diverse ethnic and socio-demographic communities. 
Patients were included on meeting the following criteria:  
• discontinued antipsychotic medication for any reason 
• had a clinical diagnosis of FEP conforming to ICD-10 codes F20-29, 
F30.2, F31.2, F31.5, F32.3 and F33.318 (due to the diagnostic uncertainty 
during the early stages of psychosis, a broad diagnostic range was 
chosen) 
• experienced a significant reduction of symptoms as judged by the clinical 
team prior to discontinuing medication (i.e. had recovered) 
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Patients were excluded if they had i) discontinued antipsychotic medication for 
less than four weeks, or ii) less than four weeks antipsychotic treatment prior to 
discontinuation, (as these time periods were considered too short to be defined 
as discontinuation or as an effective treatment episode). Patients with 
insufficient case notes were also excluded. 
Study design 
Quantitative data were obtained from retrospective electronic case-note review. 
Case records were analysed from the point medication was discontinued. The 
follow-up period was until: an occurrence of a relapse; the end of the 12 month 
study period; or the end of the patient’s case record if less than 12 month’s 
follow-up data (as this could b  accounted for by statistical analysis). All data 
were extracted by the author and were based on routine assessment by 
clinicians as documented in BSMHFT electronic patient records.  
Procedure  
The study protocol was disseminated to all clinical teams within the Birmingham 
EIS. Clinical teams identified patients who had discontinued medication 
between 2012 and 2015. Case notes of eligible patients were subsequently 
screened by the author using the eligibility criteria to determine the final sample. 
Ethical approval 
The study protocol was approved by BSMHFT Research and Innovation 
department and by the BMedSc Population Sciences and Humanities Internal 
Ethics Review Committee (IERC). In accordance with National Research Ethics 
Service (NRES) guidelines for a study involving previously collected routine 
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clinical data, specific consent procedures were not required 19 and thus the 
sample consisted of all patients who met the eligibility criteria.  
Outcome measures 
Relapse  
Relapse was defined as a return of symptoms requiring one of the following: home 
treatment, an informal mental health admission to hospital, a compulsory admission 
under the Mental Health Act (2007)20, or was based on the clinician’s judgement of 
having a relapse. This definition is representative of the BSMHFT EIS procedure to 
detect a relapse of symptoms. Relapse evaluated was the first relapse following the 
patient’s FEP. The relapse status, definition and time to relapse were recorded.   
Predictor variables 
A standard pro-forma targeted pre-defined socio-demographic and clinical 
factors, and was developed from a systematic review that explored factors 
associated with relapse in FEP.10 Socio-demographic variables were evaluated 
upon study entry and included: age, gender, ethnicity, marital status, education 
level, accommodation, employment status and smoking status. Accommodation 
status was categorised into settled versus not settled; not settled was defined 
as being in supported housing or temporary accommodation.  
Clinical variables were: clinical diagnosis, psychiatric co-morbidities, psychiatric 
family history, number of previous psychiatric hospital admissions, substance 
misuse, age at onset of psychosis, duration of untreated psychosis (DUP), 
duration of untreated illness (DUI), duration of antipsychotic treatment prior 
to discontinuation and type of antipsychotic medication (oral or depot). Due to 
the sample only including FEP patients, previous psychiatric hospital 
Page 8 of 26Early Intervention Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
 
admissions were evaluated prior to the patient’s FEP. DUP was defined as the 
period (in days) between first appearance of psychotic symptoms and the onset 
of criterion treatment (defined as antipsychotic treatment for more than two 
weeks). DUI was defined as the interval (in days) between the onset of non-
specific symptoms and the onset of criterion treatment. Both DUP and DUI 
data were based on routine standardised clinical interview as recorded in case 
notes.  
Statistical analysis 
A survival analysis was used to estimate the cumulative rate of relapse, with 
censoring of data to account for differentiated duration of follow-up of study 
subjects. Data were censored if no relapse occurred during follow-up.  
Cox proportional hazards regression was used to identify predictors of relapse 
by examining time to relapse and its relationship with independent variables. 
Proportional hazard assumption was assessed graphically using log minus log 
survival plots. Univariate Cox proportional hazards regression analysis was first 
performed on each potential predictor. Variables with P ≤0.1 were entered into a 
multivariate Cox proportional hazards model.  A forward stepwise likelihood 
ratio for variable selection was used in the multivariate model, with P <0.05 as 
the entering criterion. Missing values were excluded from the analysis. A similar 
analysis was conducted in patients who did not relapse despite stopping 
medication to identify factors associated with non-relapse. 
Results  
A total of 133 patients were identified by the clinical teams’ to have discontinued 
antipsychotics. Following assessment of eligibility, 70 (52.6%) were excluded 
Page 9 of 26 Early Intervention Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
 
from the study for the following reasons: insufficient case notes (n = 29, 41.4%); 
not meeting inclusion criteria (N=21, 30%) and discontinuation period of less 
than four weeks (n = 20). For those excluded for not meeting the inclusion 
criteria (n=21, 30%), 18 were due to partial non-concordance (i.e. not fully 
discontinued medication) and the remaining 3 due to a reduction in symptoms 
being deemed insignificant (as judged by the clinical team). Thus, data were 
collected for 63 patients. 
Sample characteristics 
Table 1 summarises the socio-demographic and clinical characteristics of the 
sample.  
The sample was 73% male and the median age at discontinuation was 22 years 
(IQR = 6). The largest ethnic group was Asian (n = 22, 35.0%), followed by 
White (n = 17, 27.0%) and Black (n = 13, 20.6%). Two-thirds of the sample 
were classified as not being in education, employment or training (NEET) (n = 
42, 66.7%). The most common diagnosis categories were psychosis not 
otherwise specified (NOS) (n = 24, 38.1%) and schizophrenia (n = 21, 33.3%). 
Prior to discontinuation, the median duration of antipsychotic treatment was 8.5 
months (IQR = 11.3; range 1-36), of which oral medication was the most 
common type (n = 53, 84.1%). The median duration of follow up was 6 months 
(IQR = 6 months). 
Relapse 
Out of the 63 patients, 36 relapsed (57%) by the end of the 12 months; of those 
that relapsed, the majority resulted in either an informal or compulsory hospital 
admission (n = 19, 52.8%), with a greater proportion of compulsory admissions 
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(n = 11, 30.6%). Taking into account censoring, the Kaplan-Meier estimate of 
the proportion relapsed at, or earlier than 12 months was 67% (95% confidence 
interval (CI), 54%, 80%) (Figure 2). The median time to relapse was 8 months 
(95% CI, 6.03, 9.97).   
Given the differentiated length of antipsychotic treatment prior to 
discontinuation, patients were grouped into: ≤12 months antipsychotic treatment 
(n = 42, 66.7%) and >12 months treatment (n = 20, 31.7%). No significant 
differences were found in time to relapse in these two groups. (Χ2 = 0.001, d.f. = 
1, P = 0.978).  
Predictors of relapse 
Several of the socio-demographic and clinical variables explored were found to 
be statistically insignificant (P >0.05) in the univariate analysis, and were: age at 
discontinuation, marital status, education level, accommodation, diagnosis, age 
at onset of FEP, DUP, DUI, psychiatric co-morbidities, psychiatric family history, 
duration of antipsychotic treatment and type of antipsychotic medication.  
Results of the relapse predictors in the univariate Cox model analysis with P 
≤0.1 are shown in Table 2. Significant univariate predictors included male 
gender, NEET, number of previous psychiatric hospital admissions and 
substance misuse. Three independent predictors for relapse were identified 
from the multivariate Cox model analysis (Table 2).  Patients who were male 
had a 3.7 times higher risk of relapse (Exp B = 3.72; 95% CI, 1.42, 9.78; P = 
0.008). NEET status was associated with a two-fold increase in relapse risk 
when compared to being in education, training or employment (Exp B = 2.24; 
95% CI, 1.01, 4.97; P = 0.047). The number of previous psychiatric hospital 
Page 11 of 26 Early Intervention Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
 
admissions was identified as a highly significant clinical predictor, with the risk 
of relapse increasing by approximately two times with every one unit increase in 
previous hospital admission (Exp B = 1.94; 95% CI, 1.31, 2.88; P = 0.001).  
None of the identified risk factors were found to be statistically significant in 
predicting non-relapse in this sample of patients with first episode psychosis 
who had stopped their medication. 
Discussion 
This study sought to address the “real world” relapse rate and to identify which 
factors (socio-demographic and clinical) were associated with relapse in a 
sample of FEP patients, who had discontinued antipsychotic medication. 
Approximately two-thirds of the sample relapsed within 12 months following 
discontinuation of antipsychotics, with male gender, NEET and increasing 
number of previous psychiatric hospitalisations being independently associated 
with a higher risk of relapse.  
Relapse 
This study’s relapse rate of 67% is in keeping with the literature, reporting 
between 41% and 80% of FEP patients who discontinue medication go on to 
relapse within the first year.3,7-9 The higher relapse rates reported 
(approximately 80%7-9) may be explained by the use of symptom-based 
definitions and the intensive follow up and monitoring that existed, allowing 
detection of relapses earlier. The relapse criterion for this study was less 
stringent, which was reflected by the high hospitalisation rate (52%) among 
those that relapsed, in comparison to previous studies.6-8 Nevertheless, it was 
based on the normal stepwise procedure used by the EIS to detect a relapse, 
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therefore likely to be better representative of “real world” clinical practice. 
Additionally, previous research conducted by Chen et al.8 estimated a more 
pragmatic relapse rate (69%) based on information from case notes, including 
only relapses deemed clinically significant, which is comparable to the relapse 
estimated in this study. 
The high hospitalisation rate among those who relapsed demonstrated that this 
study captured clinically significant relapses. This highlights the need for closer 
follow-up of patients once they are known to discontinue medication in order to 
identify relapses earlier before pronounced deterioration occurs. It would be 
useful for future studies to not only quantify relapse rates but also evaluate the 
clinical impact of the relapses. 
An important finding was that relapse was not found to be related to the 
duration of previous antipsychotic medication (which ranged from 1 month to 36 
months; median treatment duration being 8.5 months). This is concurrent with 
research by Chen et al.8 Furthermore, from previous discontinuation trials, there 
is no apparent indication of reduced relapse risk with longer treatment periods. 
Discontinuation after 3, 12 and 24 months in three separate trials all reported 12 
month relapse rates of around 80%.7,8,21 This has implications for clinical 
practice, and suggests that lengthening treatment after a FEP does not reduce 
the relapse risk. However, the optimum point in time at which medication can 
safely be discontinued has yet to be established. 
Predictors of relapse  
The strongest predictor was male gender, which was associated with 
approximately a four-fold increase in risk of relapse. Previous studies have 
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been mixed with regards to the relationship between gender and relapse, with 
some suggesting an association13,14 while others have failed to show any 
association.3,12 Nonetheless, generally in FEP patients, gender effects have 
been reported with regards to functional outcome; male patients have been 
shown to have poorer functional outcome after a first-episode, suggesting 
males may have an increased vulnerability to relapse.13 Noteworthy, male 
gender has been reported to be a predictor of medication discontinuation22 and 
so the high proportion of males in this sample may have enhanced the apparent 
difference in relapse risk. Nevertheless, this higher proportion of males to 
females is compatible with the gender split seen in this EIS.23 
NEET was associated with an approximately two times increase risk in relapse 
compared to those in employment, education or training. This finding ties in with 
a FEP follow-up study reporting early vocational recovery to be associated with 
longer term recovery.24 Early vocational recovery is considered a key 
component of recovery and it has been observed that those who only have one 
episode and recover fully are less likely to be NEET.24 NEET could be used as 
a broad measure of poor functional outcome and suggests the importance of 
interventions facilitating vocational recovery.    
The association between previous number of psychiatric hospital admissions 
and increased relapse risk is concurrent with studies examining predictors of 
hospital readmission in schizophrenia.25,26 It has been shown that a history of 
hospitalisation is associated with a higher chance of earlier rehospitalisation in 
patients with schizophrenia.27 Although in this study previous psychiatric 
admissions related to admissions prior to the patients’ FEP diagnosis,  
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hospitalisation typically indicates a higher level of symptom severity 
experienced by patients. Therefore, it could suggest patients with previous 
psychiatric admissions (prior to FEP) go onto have a more unstable illness. 
Strengths and limitations 
The diverse ethnic sample, the inclusion of all-cause discontinuation and 
patients not limited to those with motivation and capacity to consent allowed an 
estimate of relapse which is perhaps more generalisable to typical clinical 
practice.  
However, these findings must be interpreted in light of a number of limitations.  
The method used to determine the sample likely introduced recall and selection 
biases. The method involved clinicians identifying patients who had 
discontinued medication; clinicians are more likely to recall those patients who 
had previously discontinued medication which resulted in a relapse, likely 
inflating the relapse estimate. Furthermore, patients who discontinued 
medication covertly and those who had successfully discontinued may have 
been less likely to have been identified.  These biases perhaps could have been 
reduced through screening a random selection of patients, stratified by 
demographic and clinical factors, within the EIS using the eligibility criteria. 
Plasma antipsychotic levels monitoring would be the ideal way to establish 
adherence to medication, which was not available in this study due to the 
design constraints. 
The reliability of the relapse and predictor estimates were further limited by the 
small sample size. The sample size may have been insufficient to detect 
weaker predictors and was also restricted by the quality of the case notes: a 
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high proportion of the potentially eligible sample were excluded due to 
insufficient case notes (41%) and it is possible a proportion of these might have 
successfully fulfilled the eligibility criteria.  
It is important to note that for inclusion, patients were judged as having 
significant reduction in symptoms before discontinuation; however, the time 
period for the recovery was not specified, which could have been a factor 
associated with relapse. Other potentially important relapse factors were not 
captured, such as level of insight and past adherence. Larger sample sizes and 
prospective longitudinal studies are required to be able account for these 
limitations.  
Conclusion 
Relapse is common in “real world” clinical practice following discontinuation of 
antipsychotic medication following recovery from a FEP. It is important for 
clinicians to inform patients who wish to discontinued their medication of the 
high relapse rates, and should ensure closer monitoring of patients who 
discontinue medication. Patients who are male, NEET status and have a history 
of psychiatric admissions should be recognised by health care professionals as 
having an increased risk of relapse, and suggests continued medication in 
these patients. However, these findings need to be replicated in larger 
independent samples. It may also be useful for future work to identify those 
patients who can discontinue medication without risk of relapse through 
investigating factors that may be protective. This will further aid clinicians’ 
decision-making when confronted with patients requesting discontinuation.  
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Table 1. Sample characteristics (N=63) 
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Socio-demographic variables N (%) or Median (IQR) 
Gender 
Male 
Female 
46 (73.0) 
17 (27.0) 
Age (years)  22 (6) 
Ethnicity 
White 
Asian 
Black 
Mixed/Multiple 
Other 
17 (27.0) 
22 (35.0) 
13 (20.6) 
6 (9.5) 
5 (7.9) 
Marital status 
Single/separated/divorced 
Married/cohabiting 
56 (88.9) 
7 (11.1) 
Accommodation 
Settled 
Not settled 
58 (92.1) 
5 (7.9) 
Employment status 
NEET 
In education/training 
Employed 
42 (66.7) 
12 (19.0) 
9 (14.3) 
Education level 
Education to 16 only 
Education to 18 
Higher education 
46 (73.0) 
9 (14.3) 
8 (12.7) 
Smoking status 
Non smoker 
smoker 
34 (54.0) 
29 (46.0) 
Clinical variables N (%) or Median (IQR) 
Age at onset of FEP (years)  21 (5) 
Diagnosis 
Schizophrenia 
Delusional disorder 
Schizoaffective disorder 
Acute and transient psychosis 
Psychosis NOS 
Mania with psychosis 
Depression with psychosis 
21 (33.3) 
2 (3.2) 
4 (6.3) 
2 (3.2) 
24 (38.1) 
9 (14.3) 
1 (1.6) 
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Table 2. Predictors of relapse in univariate and multivariate Cox proportional hazards 
regression analysis. 
DUP (days)†  55 (112) 
DUI (days)‡  270 (619) 
Psychiatric co-morbidities 
Yes 
No 
14 (22.2) 
49 (77.8) 
Psychiatric family history 
Yes 
No 
29 (46.0) 
34 (54) 
Number of previous psychiatric 
hospital admissions (prior to 
FEP)§ 
 0 (1) 
Number of previous psychiatric 
hospital admissions (prior to 
FEP)¶ 
0  
≥ 1  
41 (65.1) 
22 (34.9) 
History of substance misuse 
Yes 
No 
30 (47.6) 
33 (52.4) 
Duration of antipsychotic 
treatment prior to discontinuation 
(months) # 
 8.5 (11.3) 
Type of antipsychotic medication 
Oral 
Depot 
53 (84.1) 
10 (15.9) 
Relapse 
Yes 
    Home treatment 
    Informal hospital admission 
    Compulsory hospital 
admission 
    Clinical team decision 
36 (57.0) 
4 (11.1) 
8 (22.2) 
11 (30.6) 
13 (36.1) 
FEP=first-episode psychosis; Psychosis NOS=psychosis not otherwise specified; 
DUP=duration of untreated psychosis; DUI=duration of untreated illness; N=number; 
IQR=inter-quartile range. 
† 2 data missing. 
‡ 7 data missing. 
§ continuous variable. 
¶ categorical variable. 
# 1 data missing.  
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Factors 
 Univariate model*  Multivariate model 
Exp B (95% 
CI) 
Wal
d P Exp B (95% CI) 
Wal
d P 
Socio-demographic  
GENDER         
Female 1      
Male 3.10 (1.20-8.01) 5.47 
0.019
** 3.72 (1.42-9.78) 7.10 
0.008
** 
ETHNICITY   0.066   0.419 
White 1   
NA 
 
Asian 0.49 (0.19-1.25) 1.18 0.135 0.127 
Black 1.75 (0.73-4.22) 2.25 0.214 0.429 
Other 1.71 (0.46-2.97) 1.56 0.740 0.301 
EMPLOYMENT 
STATUS         
In 
education/training/emplo
yment 
1   1  
NEET 2.55 (1.18-5.48) 5.70 
0.017
** 2.24 (1.01-4.97) 3.94 
0.047
** 
SMOKING STATUS         
Non smoker 1   
NA 
 
Smoker 1.89 (0.98-3.68) 3.56 0.059 0.724 
Clinical  
No. past psychiatric 
hospital admissions (1 
unit) 
1.96† (1.30-
2.96) 
10.4
1 
0.001
** 1.94† (1.31-2.88) 
10.9
4 
0.001
** 
SUBSTANCE MISUSE         
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No 1   
NA 
 
Yes 2.22 (1.23-4.35) 5.35 
0.002
** 0.773 
NEET=not in employment, education or training; NA=not applicable; Exp B=hazard ratio; 
CI=confidence interval. 
† Exp B (hazard ratio) represents relative increase in hazard with one unit increment in 
variable. 
*=predictors with P-value ≤0.1 in univariate analyses were entered in multivariate analysis. 
**=significant at 5% level. 
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Figure 1: Kaplan-Meier survival analysis for time to relapse following discontinuation of antipsychotic 
medication.  + censored. N=63. Cumulative relapse rate = 67%. Median time to relapse = 8 months.  
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